CN105745226B - 包含抗-磷脂酶d4抗体的药物 - Google Patents

包含抗-磷脂酶d4抗体的药物 Download PDF

Info

Publication number
CN105745226B
CN105745226B CN201480047721.6A CN201480047721A CN105745226B CN 105745226 B CN105745226 B CN 105745226B CN 201480047721 A CN201480047721 A CN 201480047721A CN 105745226 B CN105745226 B CN 105745226B
Authority
CN
China
Prior art keywords
seq
antibody
variable region
heavy chain
light chain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201480047721.6A
Other languages
English (en)
Chinese (zh)
Other versions
CN105745226A (zh
Inventor
山崎智英
远藤真由木
石田晃司
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SBI Biotech Co Ltd
Original Assignee
SBI Biotech Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SBI Biotech Co Ltd filed Critical SBI Biotech Co Ltd
Publication of CN105745226A publication Critical patent/CN105745226A/zh
Application granted granted Critical
Publication of CN105745226B publication Critical patent/CN105745226B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/916—Hydrolases (3) acting on ester bonds (3.1), e.g. phosphatases (3.1.3), phospholipases C or phospholipases D (3.1.4)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Transplantation (AREA)
  • Pulmonology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
CN201480047721.6A 2013-07-30 2014-07-30 包含抗-磷脂酶d4抗体的药物 Active CN105745226B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2013-158258 2013-07-30
JP2013158258 2013-07-30
PCT/JP2014/070661 WO2015016386A1 (en) 2013-07-30 2014-07-30 Medicament comprising anti-phospholipase d4 antibody

Publications (2)

Publication Number Publication Date
CN105745226A CN105745226A (zh) 2016-07-06
CN105745226B true CN105745226B (zh) 2020-03-06

Family

ID=51493000

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201480047721.6A Active CN105745226B (zh) 2013-07-30 2014-07-30 包含抗-磷脂酶d4抗体的药物

Country Status (17)

Country Link
US (2) US20160168266A1 (enExample)
EP (1) EP3027656B1 (enExample)
JP (3) JP6431523B2 (enExample)
KR (1) KR102367760B1 (enExample)
CN (1) CN105745226B (enExample)
AU (1) AU2014297217B2 (enExample)
BR (1) BR112016002001B1 (enExample)
CA (1) CA2919736C (enExample)
DK (1) DK3027656T3 (enExample)
ES (1) ES2736324T3 (enExample)
HU (1) HUE044469T2 (enExample)
MX (1) MX381725B (enExample)
PL (1) PL3027656T3 (enExample)
RU (1) RU2709741C2 (enExample)
SG (2) SG11201600666SA (enExample)
TR (1) TR201910330T4 (enExample)
WO (1) WO2015016386A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20210044A1 (ar) 2010-12-30 2017-06-16 Takeda Pharmaceuticals Co الأجسام المضادة لـ cd38
PL3431504T3 (pl) * 2012-01-31 2021-10-18 Sbi Biotech Co., Ltd. Przeciwciało przeciwko fosfolipazie D4
ES2736324T3 (es) * 2013-07-30 2019-12-27 Sbi Biotech Co Ltd Medicamento que comprende un anticuerpo anti-fosfolipasa D4
CN109689690B (zh) * 2016-07-15 2023-10-03 武田药品工业株式会社 用于评估对于成浆细胞和浆细胞耗竭性疗法的应答的方法和材料
CA3088199A1 (en) 2018-01-12 2019-07-18 Takeda Pharmaceutical Company Limited Subcutaneous dosing of anti-cd38 antibodies
JP7140367B2 (ja) * 2018-05-31 2022-09-21 国立大学法人 東京大学 ヒト由来サンプルにおける可溶型ｔｌｒ７の分析

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000011015A1 (en) * 1998-08-24 2000-03-02 Alphagene, Inc. Secreted proteins and polynucleotides encoding them

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69303494T2 (de) * 1992-11-13 1997-01-16 Idec Pharma Corp Therapeutische verwendung von chimerischen und markierten antikörper gegen menschlichen b lymphozyt beschränkter differenzierung antigen für die behandlung von b-zell-lymphoma
US20020146686A1 (en) * 2000-12-07 2002-10-10 Millennium Pharmaceuticals, Inc. Methods and compositions for the diagnosis and treatment of viral disease using 55092
JP2013052781A (ja) 2011-09-05 2013-03-21 Tokai Rika Co Ltd 車両用ミラー装置
PL3431504T3 (pl) * 2012-01-31 2021-10-18 Sbi Biotech Co., Ltd. Przeciwciało przeciwko fosfolipazie D4
ES2736324T3 (es) * 2013-07-30 2019-12-27 Sbi Biotech Co Ltd Medicamento que comprende un anticuerpo anti-fosfolipasa D4

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000011015A1 (en) * 1998-08-24 2000-03-02 Alphagene, Inc. Secreted proteins and polynucleotides encoding them

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
"Affinity improvement of single antibody VH domains: residues in all three hypervariable regions affect antigen binding;DAVIES J ET AL;《IMMUNOTECHNOLOGY,》;19960901;第2卷(第3期);169-179 *
Phospholipase D Family Member 4, a Transmembrane Glycoprotein with No Phospholipase D Activity, Expression in Spleen and Early Postnatal Microglia;Fumio Yoshikawa ET AL;《PLoS ONE》;20101111;第5卷(第11期);e13932 *
PLD4 ls Involved in Phagocytosis of Microglia: Expression and Localization Changes of PLD4 Are Correlated with Activation State of MicrogIia;Yoshinori Otani ET AL;《PLoS ONE》;20111115;第6卷(第11期);e27544 *

Also Published As

Publication number Publication date
MX381725B (es) 2025-03-13
KR20160034934A (ko) 2016-03-30
DK3027656T3 (da) 2019-08-05
CN105745226A (zh) 2016-07-06
HUE044469T2 (hu) 2019-10-28
ES2736324T3 (es) 2019-12-27
EP3027656B1 (en) 2019-06-26
RU2709741C2 (ru) 2019-12-19
US20210130493A1 (en) 2021-05-06
CA2919736C (en) 2022-03-22
JP6843449B2 (ja) 2021-03-17
AU2014297217A1 (en) 2016-02-18
RU2016106708A (ru) 2017-09-01
US20160168266A1 (en) 2016-06-16
JP2016534022A (ja) 2016-11-04
BR112016002001B1 (pt) 2023-04-25
SG10201800592SA (en) 2018-03-28
SG11201600666SA (en) 2016-02-26
TR201910330T4 (tr) 2019-07-22
MX2016001193A (es) 2016-05-26
BR112016002001A2 (pt) 2017-08-29
JP2019014759A (ja) 2019-01-31
WO2015016386A1 (en) 2015-02-05
EP3027656A1 (en) 2016-06-08
JP6431523B2 (ja) 2018-11-28
KR102367760B1 (ko) 2022-02-24
JP2019214621A (ja) 2019-12-19
RU2016106708A3 (enExample) 2018-03-30
CA2919736A1 (en) 2015-02-05
PL3027656T3 (pl) 2019-10-31
AU2014297217B2 (en) 2020-01-16

Similar Documents

Publication Publication Date Title
US10604576B2 (en) Antibodies and immunocytokines
JP6412072B2 (ja) 抗ヒト受容体型プロテインチロシンホスファターゼσ抗体
JP6843449B2 (ja) 抗ホスホリパーゼｄ４抗体を含む医薬
JP7244102B2 (ja) 抗ホスホリパーゼｄ４抗体
JP2022529350A (ja) アンタゴニスト抗ｃｄ７抗体

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant